{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+inhibitor&page=2",
    "query": {
      "intervention": "Cytochrome P450 inhibitor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+inhibitor&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+inhibitor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T21:53:11.037Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01568411",
      "title": "A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "TD-1211",
          "type": "DRUG"
        },
        {
          "name": "TD-1211+ itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glycyx Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-04",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01568411"
    },
    {
      "nct_id": "NCT06004947",
      "title": "A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "CCX168",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2016-01-14",
      "completion_date": "2016-06-10",
      "has_results": false,
      "last_update_posted_date": "2023-08-22",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06004947"
    },
    {
      "nct_id": "NCT03512548",
      "title": "Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Relacorilant 350mg",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Relacorilant 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2018-04-10",
      "completion_date": "2019-08-23",
      "has_results": false,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512548"
    },
    {
      "nct_id": "NCT03222310",
      "title": "A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-07-18",
      "completion_date": "2017-09-06",
      "has_results": false,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222310"
    },
    {
      "nct_id": "NCT00068770",
      "title": "Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2003-10",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 7,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068770"
    },
    {
      "nct_id": "NCT04959266",
      "title": "A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampicin",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 5,
      "start_date": "2021-06-28",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 3,
      "location_summary": "Portland, Oregon • Austin, Texas • Dallas, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04959266"
    },
    {
      "nct_id": "NCT03614455",
      "title": "Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Milademetan",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2018-07-13",
      "completion_date": "2018-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03614455"
    },
    {
      "nct_id": "NCT05712265",
      "title": "Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antipsychotic Induced Weight Gain",
        "Non-alcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Miricorilant",
          "type": "DRUG"
        },
        {
          "name": "Fluvoxamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 26,
      "start_date": "2023-01-24",
      "completion_date": "2023-02-23",
      "has_results": false,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05712265"
    },
    {
      "nct_id": "NCT01754116",
      "title": "A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744 30 mg oral",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 3 mg oral + GSK1265744 30mg oral",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 400 mg (200 nm)",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 400 mg (1 micro m)",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 400 mg (5 micro m)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2013-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01754116"
    },
    {
      "nct_id": "NCT01181427",
      "title": "Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "ABT-267",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Blood Sample Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cytochrome P450 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 137,
      "start_date": "2010-08",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-24",
      "last_synced_at": "2026-10-06T21:53:11.037Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Waukegan, Illinois • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Waukegan",
          "state": "Illinois"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01181427"
    }
  ]
}